Trial Information

Peripheral T cell lymphoma patients of all subtypes according to WHO are treated with an
induction of 6 cycles of CHOP-etoposide-14 (if below 60 years of age) oder CHOP-14. If at
least a PR is reached, consolidation with alemtuzumab, total dose 133 mg, is given i.v.

Inclusion Criteria:

- all risk groups in international prognostic index

- diagnosis of aggressive T-cell-lymphoma, confirmed by an excisional biopsy of a lymph
node or by sufficiently extensive biopsy of an extranodal involvment, if there is no
lymph node involvment.

Outcome Measure:

Outcome Description:

A descriptive approach for the primary endpoint was chosen: Adherence to schedule of alemtuzumab consolidation (number of cycles, dosing, time) - comparison of planned vs given in pts receiving alemtuzumab

Outcome Time Frame:

average of 24 weeks (treatment duration)

Safety Issue:

Yes

Principal Investigator

Lorenz Truemper

Investigator Role:

Principal Investigator

Investigator Affiliation:

German High Grade Non Hodgkin´s Lymphoma Study Group

Authority:

Germany: Paul-Ehrlich-Institut

Study ID:

DSHNHL-2003-1

NCT ID:

NCT01806337

Start Date:

July 2003

Completion Date:

February 2011

Related Keywords:

Peripheral T-cell Lymphoma

peripheral T cell lymphoma

alemtuzumab

consolidation

Lymphoma

Lymphoma, T-Cell

Lymphoma, T-Cell, Peripheral

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.